Dorottya Kocsis

Role of Altered Expression of miR-146a, miR-155, and miR-122 in Pediatric Patients with Inflammatory Bowel Disease.

Background:Evidence suggests the central role of tumor necrosis factor (TNF)-&agr; in the pathomechanism of inflammatory bowel disease (IBD); however, its effect on epigenetic factors, including small non-coding microRNAs (miRs), is less known. Our present aim was the comparative investigation of the expression of TNF-&agr; and immune response–related miRs in children with Crohns disease (CD) and ulcerative colitis (UC). Methods:Fresh-frozen (FF) and formalin-fixed, paraffin-embedded (FFPE) biopsies were used to analyze the expression of miR-146a, -155, -122, and TNF-&agr; by real-time reverse transcription polymerase chain reaction in macroscopically inflamed (CD: 12 FFPE and 24 FF; UC: 10 FF) and intact (CD: 12 FFPE; 14 FF) colonic biopsies of children with IBD and controls (16 FFPE; 23 FF). The expression of miR-146a, -155, and -122 was also determined in TNF-&agr;–treated HT-29 colonic epithelial cells. Results:Increased expression of TNF-&agr; was observed in the colonic mucosa of children with CD and UC in comparison with controls. Expression of miR-146a and -155 was higher in the inflamed mucosa of children with CD and UC than in the intact mucosa. Expression of miR-122 elevated in the macroscopically intact colonic regions of CD compared with controls and patients with UC. In HT-29 cells, TNF-&agr; treatment increased the expression of miR-146a and -155, but not that of miR-122. Conclusions:Our results showed altered expression of miR-146a, -155, and -122 in the colonic mucosa of children with IBD and in TNF-&agr;–treated colonic epithelial cells. Our data suggest the TNF-&agr;–related involvement of these miRs in the pathogenesis of IBD.

Coeliac disease in a 15-year period of observation (1997 and 2011) in a Hungarian referral centre

AIMS The aim of this study is to evaluate the experience of a single coeliac centre over a 15-year-long study period (between November of 1997 and September of 2011). PATIENTS AND METHODS Charts of 178 patients (139 females) with coeliac disease were retrospectively evaluated. Tests performed: multiple duodenal biopsies, anti-tissue transglutaminase and anti-endomysium antibodies, body mass index calculation, osteodensitometry, evaluation of disorders associated with coeliac disease, and implementation of family screening. RESULTS Histological samples were available in 133 cases, distribution according to Marsh-Oberhuber classification: M0 in 7%, M1-M2 in 4%, M3a in 26%, M3b in 13%, and M3c in 50% of cases, respectively. Anti-tissue transglutaminase and anti-endomysium antibody tests were available in 158 cases, 132/158 showed seropositivity. Mean body mass index values were 23.05kg/m(2) for males, and 21.07kg/m(2) for females, respectively. Osteodensitometry showed normal values in 46%, osteopenia in 36%, and osteoporosis in 18% of cases, respectively. Coeliac disease associated disorders was present in 63/178 (35%) patients. Ninety coeliacs brought 197 first degree relatives for screening, with 47/197 (23%) relatives proving to have coeliac disease. Correlations between anti-tissue transglutaminase antibody titres and Marsh-Oberhuber classification, and anti-tissue transglutaminase antibody titres and bone mineral density values were found to be statistically significant (p=0.0011, and p=0.001, respectively). CONCLUSIONS Coeliac disease can become overt at any age. Female predominance is significant. Histology usually showed advanced villous atrophy. Mean body mass index values were within normal range. The high prevalence of associated disorders is also noted. The prevalence of 24% of coeliac disease among first degree relatives underlines the necessity of family screening.

Influence of inhomogeneous static magnetic field-exposure on patients with erosive gastritis: a randomized, self- and placebo-controlled, double-blind, single centre, pilot study

This pilot study was devoted to the effect of static magnetic field (SMF)-exposure on erosive gastritis. The randomized, self- and placebo-controlled, double-blind, pilot study included 16 patients of the 2nd Department of Internal Medicine, Semmelweis University diagnosed with erosive gastritis. The instrumental analysis followed a qualitative (pre-intervention) assessment of the symptoms by the patient: lower heartburn (in the ventricle), upper heartburn (in the oesophagus), epigastric pain, regurgitation, bloating and dry cough. Medical diagnosis included a double-line upper panendoscopy followed by 30 min local inhomogeneous SMF-exposure intervention at the lower sternal region over the stomach with peak-to-peak magnetic induction of 3 mT and 30 mT m−1 gradient at the target site. A qualitative (post-intervention) assessment of the same symptoms closed the examination. Sham- or SMF-exposure was used in a double-blind manner. The authors succeeded in justifying the clinically and statistically significant beneficial effect of the SMF- over sham-exposure on the symptoms of erosive gastritis, the average effect of inhibition was 56% by p = 0.001, n = 42 + 96. This pilot study was aimed to encourage gastroenterologists to test local, inhomogeneous SMF-exposure on erosive gastritis patients, so this intervention may become an evidence-based alternative or complementary method in the clinical use especially in cases when conventional therapy options are contraindicated.

Does dermatitis herpetiformis result in bone loss as coeliac disease does?: a cross sectional study

INTRODUCTION AND OBJECTIVES coeliac disease (CD) and its cutaneous manifestation, dermatitis herpetiformis are both (DH) gluten-sensitive diseases. Metabolic bone disease is common among patients with CD, even in asymptomatic forms. Data are scarce about bone density in patients with dermatitis herpetiformis. The aim of our study was to compare bone mineral density (BMD) of celiac and dermatitis herpetiformis patients. METHODS 34 coeliac patients, 53 with dermatitis herpetiformis and 42 healthy controls were studied. The mean age was 38.0 +/- 12.1, 32.18 +/- 14.95, 35.33 +/- 10.41 years in CD, dermatitis herpetiformis, and healthy controls, respectively. Bone mineral density of the lumbar spine, the left femoral neck and radius were measured by dual-energy X-ray absorptiometry. Low bone density, osteopenia and osteoporosis were defined as a body mass density (BMD) T-score between 0 and -1, between -1 and -2.5, and under -2.5, respectively. RESULTS at lumbar region, consisting of dominantly trabecular compartment, a decreased BMD was detected in 49 % (n = 26) patients with dermatitis herpetiformis, 62 % (n = 21) of CD patients, and 29 % (n = 12) of healthy controls, respectively. Lower BMD were measured at the lumbar region in dermatitis herpetiformis and CD compared to healthy subjects (0.993 +/- 0.136 g/cm2 and 0.880 +/- 0.155 g/cm2 vs. 1.056 +/- 0.126 g/cm2; p < 0.01). Density of bones consisting of dominantly cortical compartment (femoral neck) did not differ in dermatitis herpetiformis and healthy subjects. CONCLUSIONS our results show that a low bone mass is also frequent among patients with dermatitis herpetiformis. Bone mineral content in these patients is significantly lower in those parts of the skeleton which contain more trabecular than cortical bone.

Genetic and epigenetic aspects of celiac disease

Genetic background of coeliac disease has been subjects to intensive research since decades. However, only results of HLA phenotyping have been taken over to routine clinical practice. Meanwhile, data on the role of epigenetical factors in the manifestation of diseases have been emerging. In coeliac disease, there are several questions both in the fields of genetics and epigenetics yet to be answered. In this review, a cross section of current knowledge on these issues is presented with special interest regarding the future clinical applications.

[Retrospective evaluation of the ten-year experience of a single coeliac centre].

UNLABELLED Coeliac disease (gluten-sensitive enteropathy, sprue) is a chrocic disorder of the small bowel leading to malabsorption. AIMS charts of all patients with coeliac disease treated at the 2nd Department of Medicine, Semmelweis University were evaluated. PATIENTS AND METHODS The authors retrospectively analysed the results of a total of 132 patients with coeliac disease (107 females and 25 males; mean age, 37 years; median, 35 years; range, 19-78 years) attending the centre between 1999 and 2010. The authors routinely performed the following investigations in patients with suspected coeliac disease: multiple biopsies taken from the duodenum, tissue transglutaminase antibody or endomysial antibody based serology, body mass index calculation, osteodensitometry, evaluation of disorders associated with coeliac disease, family history for coeliac disease, and implementation of family-screening for coeliac disease given the agreement of the index patients. RESULTS Histological samples were available in 101 cases, and distributions of data according to the Marsh-classification were as follows: negative in 9%, M3a in 27%, M3b in 18%, and M3c in 46% of cases, respectively. Serological results were available in 117 cases. 93/117 (79%) showed seropositivity. Body mass index was calculated for 95 patients, and the mean value for males was 22.4 kg/m² (range, 17-30.3 kg/m²), whereas the mean value for females was 20.7 kg/m² (range, 15.2-30.4 kg/m²). Osteodensitometry was performed in 90 patients; 45 patients (50%) proved normal, 31 (34%) had osteopenia, and 15 (26%) had osteoporosis. Coeliac disease associated disorders were present in 45/132 patients (34%; 6 males). Associated disorders were as follows: 15 dermatitis herpetiformis Duhring, 15 thyroid diseases (5 hypo- and 10 hyperthyroidism), 6 Crohns disease, 3 selective IgA-deficiency, 2 endometrioses, 1 systemic lupus erythematosus, 1 myasthenia gravis, and 1 type-1 diabetes mellitus. Sixty-four of the 132 index patients brought 133 first-degree relatives for family screening (serology), where 26/133 (19.5%; 17 females) first-degree relatives proved to suffer from coeliac disease. CONCLUSIONS The age distribution of this cohort demonstrates that coeliac disease can present at any age. Similarly to those of other coeliac disease centres, female predominance is significant. Histology usually showed advanced villous atrophy. Serological results were usually in conjunction with the histological results and proved to be useful for monitoring dietary compliance and for accomplishing family screening. The mean body mass index values were in the normal range confirming that adult patients with coeliac disease are usually not malnourished. The 20% prevalence of coeliac disease among first-degree relatives underlines the necessity of family screening.

Koffein: hagyományos és új terápiás indikációk, valamint felhasználás dermatológiai modellvegyületként

Absztrakt: A kavefogyasztas a XV. szazadtol kezdve terjedt el vilagszerte. Elterjedese nemcsak a kaveital kivalo aromajanak, hanem a benne levő hatoanyagoknak, igy elsősorban a koffeinnek koszonhető. Ebben a tanulmanyban ismertetjuk a koffein komplex teljesitmenyfokozo hatasanak hattereben allo mechanizmusokat, illetve bemutatjuk az utobbi evtizedekben egyre szelesebb korben folytatott, uj indikacios teruletekre iranyulo kutatasokat. Szamos vizsgalat foglalkozik a neuroprotektiv (Alzheimer- es Parkinson-kor-ellenes) es hepatoprotektiv hatasokkal, illetve kulon kiterunk az egyik legperspektivikusabb uj teruletre, a bőr tumoros elvaltozasainak megelőzeseben jatszott szerepere. Ez utobbi mind sejtes rendszerekben, mind pedig in vivo korulmenyek kozott bizonyitast nyert. Egyebek mellett ezeken az eredmenyeken alapul a koffein, illetve a kave kozmetikai es bőrgyogyaszati keszitmenyekben tortenő alkalmazasa. Erősen hidrofil tulajdonsaga miatt a koffeint transdermalis kiserletekben modellanyagkent is felhasznalj...Coffee consumption had already been described in the 15th century. The spreading of coffee drinking was not only a consequence of its delicious aromatic taste, but also of its pharmacological effects, especially due to its caffeine content. In this review, the mechanisms behind its complex stimulatory effects and the latest studies on the possible new therapeutic indications of caffeine are summarized. Several papers reported the neuroprotective (in Alzheimers and Parkinsons disease) and hepatoprotective profiles of caffeine, and we show the most promising new results about its preventive properties in dermal malignancies. These findings were described both in cell cultures and in vivo. The application of caffeine and coffee in cosmetology and dermatological products is based on their antioxidant property and on the above-mentioned beneficial effects. Caffeine is also presented here as a dermatological model drug due to its hydrophilic profile. It can be used for designing and comparing different novel drug formulations, although beside the transcellular route, the follicular and transappendageal pathways play also important roles in its skin penetration. Taken together, caffeine molecule has many recently discovered beneficial pharmacological effects, but one should be careful with its excessive consumption. It can result in several adverse events if overdosed and in case of regular intake of high doses, after abandonment, withdrawal symptoms may appear. Orv Hetil. 2018; 159(10): 384-390.

Intestinalis zsírsavkötő fehérje: az enterocytakárosodás markere akut és krónikus gasztroenterológiai kórképekben

Intestinal fatty acid binding protein, a small cytosolic protein abundantly present in mature enterocytes of small and large intestine, has proven to be a sensitive marker for damage to the intestinal epithelium. Upon cellular damage of the enterocyte, intestinal fatty acid binding protein is readily released into the systemic circulation, passes through the glomerular filter and can be detected in the urine. In this review, the authors review studies on the application of this protein as a biomarker in acute and chronic gastrointestinal diseases.Intestinal fatty acid binding protein, a small cytosolic protein abundantly present in mature enterocytes of small and large intestine, has proven to be a sensitive marker for damage to the intestinal epithelium. Upon cellular damage of the enterocyte, intestinal fatty acid binding protein is readily released into the systemic circulation, passes through the glomerular filter and can be detected in the urine. In this review, the authors review studies on the application of this protein as a biomarker in acute and chronic gastrointestinal diseases.

Eosinophil oesophagitis étrendi és gyógyszeres vonatkozásai

Absztrakt Az eosinophil oesophagitis a nyelőcső kronikus, antigenmedialt gyulladasa. A nyelőcsőben oralis es/vagy aeroantigenek altal indukalt eosinophilgranulocyta-infiltracio, nyalkahartya-hyperplasia es a subepithelialis retegek fibrosisa szűkulethez, dysphagiahoz es falatelakadashoz vezethet. A betegseg gyakran tarsul mas allergias korkepekkel, mint az asthma vagy az atopias dermatitis. Az eosinophil oesophagitis kezelesenek sarokkovei az elkerulő dieta es a helyileg alkalmazott, gyulladascsokkentő szteroidkezeles. A szerzők attekintik a jelenleg rendelkezesre allo kezelesi strategiakat. Orv. Hetil., 2015, 156(23), 927–932.